Akari Therapeutics, Plc AKTX
Set alert
As of Nov 3, 10:13 AM ET
- YTD
- -27.77%
- 1 year
- -71.21%
- Open
- 8.39
- Prev close
- 7.57
- Mkt cap
- 19.15M
- Vol
- 17.29K
- Avg vol
- 62.63K
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 7.99
- High
- 8.61
- Forward P/E
- -0.29
- Beta
- 0.95
- Short ratio
- 1.92
- Inst. own
- 0.51%
- Dividend
- 0.00
- Ex-div date
- Earnings
- May 6, 2024
- 50-d avg
- 1.78
- 200-d avg
- 2.41
- 1y target
- 0.00
5D chart
Signals (81)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Nov 3, 10:00 AM | 13 minutes ago |
| SMA: Bullish | Nov 3, 10:00 AM | 13 minutes ago |
| SMA: Bearish | Nov 3, 9:55 AM | 18 minutes ago |
| SMA: Bearish | Nov 3, 9:55 AM | 18 minutes ago |
| MACD: Buy Signal | Nov 3, 9:50 AM | 23 minutes ago |
| SMA: Bullish | Nov 3, 9:45 AM | 28 minutes ago |
| SMA: Bullish | Nov 3, 9:45 AM | 28 minutes ago |
| RSI: Oversold | Nov 2, 3:20 PM | 18 hours ago |
| MACD: Sell Signal | Nov 2, 1:55 PM | 20 hours ago |
| SMA: Bearish | Nov 2, 12:35 PM | 21 hours ago |
| MACD: Buy Signal | Nov 2, 11:55 AM | 22 hours ago |
| SMA: Bullish | Nov 2, 11:50 AM | 22 hours ago |
| SMA: Bullish | Nov 2, 11:50 AM | 22 hours ago |
| SMA: Bearish | Nov 2, 11:35 AM | 22 hours ago |
| MACD: Sell Signal | Nov 2, 11:35 AM | 22 hours ago |
| MACD: Buy Signal | Nov 2, 11:30 AM | 22 hours ago |
| SMA: Bullish | Nov 2, 11:25 AM | 22 hours ago |
| SMA: Bearish | Nov 2, 11:00 AM | 23 hours ago |
| SMA: Bearish | Nov 2, 11:00 AM | 23 hours ago |
| MACD: Sell Signal | Nov 2, 11:00 AM | 23 hours ago |
Newest 20 of 81.
News
4 days ago globenewswire.com
Akari Therapeutics to Highlight Novel RNA-Splicing ADC Payload Strategy at the 3rd Annual ADC Payload Summit
Presentation to explore the potential of RNA-splicing payloads to drive broad anti-tumor effects through direct cell killing along with immune activation
2 weeks ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Disc Medicine (NASDAQ:IRON) stock moved upwards by 50.4% to $85.51 during Monday's pre-market session. The company's market cap stands at $2.1 billion. DataMEDS AI (NASDAQ:MEDS) shares moved…
2 weeks ago benzinga.com
Why XCF Global Shares Are Trading Higher By Around 65%; Here Are 20 Stocks Moving Premarket
XCF Global surged 64.9% premarket after completing a business combination and forecasting 2025 revenue of $120M-$130M and EBITDA of $70M-$75M.
2 weeks ago globenewswire.com
Akari Therapeutics CEO Highlights Differentiated ADC Payload Strategy and Path Toward Clinical Development in New CEO Corner
CEO Abizer Gaslightwala discusses Akari's novel PH1 payload strategy and execution priorities supporting AKTX-101's advancement toward planned Phase 1 clinical development in mid-2027
2 weeks ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Biodexa Pharmaceuticals (NASDAQ:BDRX) stock rose 13.3% to $0.55 during Wednesday's after-market session. Impact BioMedical (AMEX:IBO) stock rose 10.77% to $3.77. The company's market cap…
3 weeks ago globenewswire.com
Akari Therapeutics Appoints Accomplished Oncology and ADC Deal Executive Vatnak Vat-Ho as Chief Business Officer to Drive Strategic Growth and Partnering
Mr. Vat-Ho's appointment adds more than 20 years of oncology, biopharma and capital markets experience, including senior roles in transactions totaling more than $25 billion in aggregate value
-
1 month ago benzinga.com
Akari Therapeutics Submits PCT/US2026/45955 To Expand Its IP Portfolio
Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with a novel RNA splicing disrupting payload, today announced the filing of…
1 month ago globenewswire.com
Akari Therapeutics Expands Intellectual Property Portfolio with PCT Filing for ADC Payload Related to RNA Splicing in Cancers
Patent filing covers PH1 payload's unique ability to disrupt multiple cancer-driving pathways in addition to its overall cytotoxic mechanism
1 month ago defenseworld.net
Akari Therapeutics PLC (NASDAQ:AKTX) Short Interest Update
Akari Therapeutics PLC (NASDAQ: AKTX - Get Free Report) was the recipient of a significant decline in short interest in the month of September. As of September 15th, there was short interest totaling…
1 month ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Biodexa Pharmaceuticals (NASDAQ:BDRX) shares moved upwards by 39.3% to $1.56 during Tuesday's pre-market session. The company's market cap stands at $1.1 million. As per the press release, H1…
-
1 month ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Scinai Immunotherapeutics (NASDAQ:SCNI) stock moved upwards by 44.6% to $2.4 during Monday's pre-market session. The company's market cap stands at $1.1 million. Definium Therapeutics…
1 month ago defenseworld.net
Akari Therapeutics (NASDAQ:AKTX) Stock Crosses Above Fifty Day Moving Average – Should You Sell?
Akari Therapeutics PLC (NASDAQ: AKTX - Get Free Report)'s stock price passed above its 50-day moving average during trading on Tuesday. The stock has a 50-day moving average of $9.65 and traded as…
1 month ago globenewswire.com
Akari Therapeutics Selected to Showcase Novel PH1 ADC Payload Platform at Leading Global Oncology, ADC and Healthcare Forums
Company invited to present alongside global pharmaceutical, biotechnology and industry leaders at five high-profile U.S. and China conferences in September
2 months ago globenewswire.com
Akari Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference
Video webcast now available here
-
2 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Biohaven (NYSE:BHVN) shares increased by 16.5% to $16.75 during Wednesday's regular session. The market value of their outstanding shares is at $2.1 billion. SCYNEXIS (NASDAQ:SCYX) stock…
2 months ago benzinga.com
Akari Targets Mid-2027 for Human Trial of Differentiated Cancer Therapy
Akari Therapeutics reports positive preclinical data for AKTX-101 in urothelial cancer, showing efficacy in models resistant to current ADCs.
-
2 months ago benzinga.com
Akari Therapeutics Announces Preclinical Data Of AKTX-101 Shows Anti-Tumor Activity Throughout Multiple Clinically Relevant Urothelial Cancer Preclinical Models
Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced new preclinical data…
2 months ago globenewswire.com
Akari Therapeutics Builds Momentum for AKTX-101 with Compelling Urothelial Cancer Data Supporting Differentiated ADC Strategy
AKTX-101 demonstrated robust anti-tumor activity across multiple clinically relevant urothelial cancer preclinical models
-
2 months ago benzinga.com
Akari Therapeutics Says Strategic Research Collaboration With Whitehawk Therapeutics Expands Potential Application Of Akari’s PH1 Platform Into Dual-Payload ADCs
Expanded the Company's strategic position in novel ADC payloads through a research collaboration on dual ADC payloads with Whitehawk Therapeutics to evaluate Akari's proprietary PH1 spliceosome…
2 months ago globenewswire.com
Akari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload Platform
AKTX-101 advancing through IND-enabling development activities toward planned initiation of Phase 1 clinical trial in mid-2027
3 months ago globenewswire.com
Akari Therapeutics Releases CEO Corner Highlighting Strategic WhiteHawk Collaboration and the Expanding Opportunity for Dual-Payload ADC Innovation
Discussion explores how combining complementary payload technologies may unlock new therapeutic opportunities while reinforcing the versatility of Akari's proprietary PH1 spliceosome-modulating…
3 months ago defenseworld.net
Akari Therapeutics (NASDAQ:AKTX) Shares Cross Below 200-Day Moving Average – Here’s What Happened
Akari Therapeutics PLC (NASDAQ: AKTX - Get Free Report)'s stock price passed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $9.24 and traded as…
3 months ago benzinga.com
Why Amazon Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
Amazon reported strong Q2 results, beating revenue and earnings estimates. Shares jumped 11.9% in pre-market trading while other stocks also saw gains/losses.
3 months ago globenewswire.com
Akari Therapeutics CEO Explains Why Growing Industry Demand for Next-Generation ADC Payloads Positions the Company at the Center of a Major Oncology Opportunity
Virtual Investor "What This Means" segment highlights strategic Whitehawk collaboration, accelerating industry validation of novel ADC payloads, and Akari's differentiated PH1 platform
-
3 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Jupiter Neurosciences (NASDAQ:JUNS) stock rose 36.4% to $0.23 during Tuesday's pre-market session. The market value of their outstanding shares is at $7.9 million. Imunon (NASDAQ:IMNN) shares…
-
3 months ago benzinga.com
Akari Therapeutics Announces Strategic Research Collaboration With Whitehawk To Conduct Preclinical Studies Evaluating PH1 Spliceosome-Modulating Payload Technology In Combination With TOP1i ADC Platform
Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced a strategic research…
3 months ago globenewswire.com
Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics
TAMPA, Fla. and LONDON, July 21, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing…
-
3 months ago benzinga.com
Maxim Group Upgrades Akari Therapeutics to Buy, Announces $30 Price Target
Maxim Group analyst Jason McCarthy upgrades Akari Therapeutics (NASDAQ:AKTX) from Hold to Buy and announces $30 price target.
-
3 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Crinetics Pharmaceuticals (NASDAQ:CRNX) shares moved upwards by 98.7% to $83.53 during Tuesday's regular session. The company's market cap stands at $4.4 billion. Tvardi Therapeutics…
3 months ago globenewswire.com
Akari Therapeutics Appoints Former AACR President and Renowned Oncology Drug Development Leader, Patricia LoRusso, D.O., to Scientific Advisory Board
Globally recognized leader in early-phase oncology clinical development and experimental therapeutics Strengthens strategic expertise as Akari advances its novel ADC payload that modulates RNA…
4 months ago globenewswire.com
Akari Therapeutics Completes Previously Announced PIPE, Strengthening Balance Sheet Ahead of Potential Key Clinical and Regulatory Milestones
Consolidated closing of recently announced $5.5 million PIPE led by existing investors, combined with an additional $2.8 million in proceeds from warrant exercises, results in approximately $8.3…
4 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 168.2% to $7.94 during Friday's after-market session. The market value of their outstanding shares is at $1.8 million. Tvardi…
5 months ago globenewswire.com
Akari Therapeutics Releases CEO Corner Reflecting on Evolving ADC Landscape and Akari's Differentiated PH1 Payload Platform Following ASCO 2026
Discussion highlights growing importance on novel ADC payloads, and Akari's ASCO data in KRAS-driven cancers and future potential
-
5 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
-
5 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Thursday's Intraday Session
-
5 months ago benzinga.com
Akari Therapeutics CEO Highlights ASCO Data Demonstrating Synergy Of AKTX-101 With Adagasrib In KRAS-Driven Cancers In Virtual Investor "What This Means" Segment
kari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced that its CEO…
5 months ago globenewswire.com
Akari Therapeutics Discusses Breakthrough Potential of AKTX-101 and Novel Spliceosome-Modulating ADC Platform in Virtual Investor “What This Means” Segment Following ASCO Abstract Acceptance
CEO Abizer Gaslightwala highlights promising ASCO data demonstrating synergy of AKTX-101 with adagasrib in KRAS-driven cancers Watch the “What This Means” video here TAMPA, Fla. and LONDON, May 28,…
-
5 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
5 months ago benzinga.com
VNET Group, Akari Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
US stock futures up, VNET Group shares down 3.8% after reporting Q1 loss of $(1.20) per share on $390.133 million sales. Other stocks also fall.
-
5 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
5 months ago feeds.benzinga.com
Why Akari Therapeutics Stock Is Falling On Tuesday?
Discover why Akari Therapeutics PLC (NASDAQ: AKTX) stock is falling on Tuesday after last week's massive 255% rally on positive preclinical cancer data.
5 months ago benzinga.com
Why Akari Therapeutics Stock Is Falling On Tuesday?
Discover why Akari Therapeutics PLC (NASDAQ: AKTX) stock is falling on Tuesday after last week's massive 255% rally on positive preclinical cancer data.
5 months ago benzinga.com
Why JOYY Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
Gainers: PHGE +97.3%, ARTL +74.8%, QTEX +52.4%, MNTX +34.4%, HLIT +28.3%, WOK +25%, CPSH +24.7%, CODX +22.7%, MDAI +22%. Losers: AKTX -25.2%, RYOJ -18.6%, DEVS -18.6%, AKAN -17%, ADTX -16.3%, LFS…
-
5 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
-
5 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
5 months ago benzinga.com
Crude Oil Edges Higher; US Consumer Sentiment Falls In May
US stocks rose, Dow gained over 400 points. S&P 500 and NASDAQ also up. Health care shares jumped, while communication services fell. University of Michigan's consumer sentiment index hit record low.…
5 months ago benzinga.com
Akari Therapeutics Stock Jumps On Promising Preclinical Data
Akari Therapeutics Plc (NASDAQ:AKTX) shares are ripping higher after the company released preclinical data showing AKTX‑101 produced synergistic activity alongside KRAS inhibition in KRAS-mutated…
5 months ago benzinga.com
Akari Therapeutics Stock Jumps On Promising Preclinical Data
Akari Therapeutics shares are surging after preclinical data showed AKTX‑101 synergized with KRAS inhibition in pancreatic cancer models.
5 months ago benzinga.com
Dow Jumps 250 Points; BJ's Wholesale Shares Fall After Q1 Results
US stocks rise with the Dow gaining 250 points. Health care shares jump while energy stocks fall. BJ's Wholesale Club stock falls 7% after earnings.
5 months ago benzinga.com
Why Estee Lauder Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
Estee Lauder (EL) shares jumped 11.8% in pre-market trading after ending discussions with Puig. Other gainers include PCLA, AKTX, LFS, BIYA, QTEX, GOVX, COHN, SQNS, and IMAX.